Abacavir/lamivudine fixed-dose combination tablet for the treatment of HIV-1 infection

Future Virology

Volumn 2, Issue 1, 2007, Pages 11-21

  Taylor, Clare L ^a   Wilkins, Edmund G L ^a  

^a NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Abacavir; HIV; Kivexa ; Lamivudine; Nucleoside reverse transcriptase inhibitor

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; CARBOVIR; COTRIMOXAZOLE; DEOXYCYTIDINE TRIPHOSPHATE; DEOXYGUANOSINE TRIPHOSPHATE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; METHADONE; NELFINAVIR; PLACEBO; RITONAVIR; RITONAVIR PLUS AMPRENAVIR; RITONAVIR PLUS FOSAMPRENAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; STAVUDINE PLUS DIDANOSINE; STAVUDINE PLUS LAMIVUDINE; TENOFOVIR; TENOFOVIR PLUS DIDANOSINE PLUS EFAVIRENZ; THYMIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE; ZIDOVUDINE PLUS ABACAVIR;

ALCOHOLISM; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DIARRHEA; DIET RESTRICTION; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FOLLOW UP; GENE SEQUENCE; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRIAL TOXICITY; MONOTHERAPY; NEPHROTOXICITY; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TABLET FORMULATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS MUTATION; WASTING SYNDROME; WATER DEPRIVATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34249329946     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.1.11     Document Type: Review

References (43)

1. Gottlieb MS, Schroff R, Schanker HM et al.: Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 305(24), 1425-1431 (1981).
2. Hymes KB, Cheung T, Greene JB et al.: Kaposis sarcoma in homosexual men - a report of eight cases. Lancet 2(8247), 598-600 (1981).
3. Tassie JM, Grabar S, Lancar R, Deloumeaux J, Bentata. M, Costagliola D: Time to AIDS from 1992 to 1999 in HIV-1 infected subjects with known dates of infection. J. AIDS 30(1), 81-87 (2002).
4. Chesney MA: Factors affecting adherence to antiretroviral therapy. CID 30(Suppl. 2), S171-S176 (2000).
5. Gazzard B: BHIVA writing committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 6(Suppl. 2), 1-61 (2005).
6. Hammer SM, Saag MS, Schechter M et al.: Treatment for Adult HIV Infection. 2006 Recommendations of the International AIDS Society - USA panel. JAMA 296(7), 296-243 (2006).
7. Maitland D, Moyle G, Hand J et al.: Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 19(11), 1183-1188 (2005).
8. Baker KL, Lou Y, Yuen GJ, Murray S, Stein D: The bioequivalence and effect of foos of a new once-aday fixed dose combination tablet of abacavir (ABC) and lamivudine (3TC). Abstract A-458. Presented at: 44th Annual ICAAC. Washington DC, USA, 30 October-2 November (2004).
9. Caparelli EV, Letendre SL, Ellis RJ, Patel P, Holland D, McCurchan JA: Population Pharmacokinetics of Abacavir in Plasma and Cerebrospinal Fluid. Antimicrob. Agents Chemother. 49(6), 2504-2506 (2005).
10. Girard PM, Katlama C, Pialoux G: VIH 6th edition (2004).
11. Bergshoeff A, Burger D, Verweij C et al.: PENTA-13 study group. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1 infected children (PENTA-13). Antivir. Ther. 10(2), 239-246 (2005).
12. Bruce RD, Altice FL, Gourevitch MN, Friedland GH: Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J. Acquir. Immune Defic. Syndr. 41, 563-572 (2006).
13. Sellers E, Lam R, McDowell J et al.: The pharmacokinetics (pk) of abacavir (ABC) and methadone (M) following co-administration: CNAA1012 (abstract 663]. Presented at: 39th Interscience Conference on Antimicrobials Agents and Chemotherapy. San Francisco, USA, 26-29 September (1999).
14. Moyle G: Resistance and cross resistance to abacavir. HIV Med. 2, 154-162 (2001).
15. Harrigan PR, Stone C, Griffin P et al.: Resistance profile of the human immunodeficiency virus type 1 reverse transcripcase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J. Infect. Dis. 181, 912-920 (2000).
16. DeJesus E, Herrera G, Teofilo E et al.: Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naïve HIV-infected adults. Clin. Infect. Dis. 39, 1038-1046 (2004).
17. Moyle GJ, DeJesus E, Cahn P, Castillo SA, Zhao H, Gordon DN: Abacavir once or twice daily combined with once daily lamivudine and efavirenz for the treatment of antiretroviral naïve HIV-infected adults: results of the Ziagen once daily in antiretroiviral combination study. J. AIDS 38(4), 417-425 (2005).
18. Bartlett JA, Johnson J, Herrera G et al.: Long term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir or stavudine. J. Acquir. Immune Defic. Syndr. (2006) (Epub ahead of print).
19. Podzamcer D, Ferrer E, Sánchez P et al.: A randomized comparison of abacavir and stavudine, combined with lamivudine/ efavirenz, in antiretroviral-naive patients. Final 96-week results (ABCDE study). Presented at: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22-25 February (2005) (Abstract 587).
20. Rodriguez-French A, Boghossian J, Gray GE et al.: The NEAT Study: A 48 week open-label study to compare the antiviral efficacy and safety of GW433908 versus Nelfinavir in antiretroviral therapy-naïve HIV-1 Infected Patients. J. AIDS 35(1), 22-32 (2004).
21. Gathe J, Ive P, Wood R et al.: SOLO: 48 week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice daily nelfinavir in naïve HIV-1-infected patients. AIDS 18, 1529-1537 (2004).
22. Gathe J, Wood R, Sanne I, DeJesus E, Schurmann D, Gladysz A et al.: Long term (120 week) antiviral efficacy of fosamprenavir /ritonavir once daily in therapy naïve patients with HIV infection: an uncontrolled, open label, single arm follow on study. Clin. Ther. 28 (5), 745-754 (2006).
23. Eron J, Yeni P, Gathe J et al.: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368, 476-482 (2006).
24. Sosa N, Hill-Zabala C, DeJesus E et al.: Abacavir and Lamivudine fixed dose combination once daily compared with abacavir and lamivudine twice daily in HIV infected patients over 48 weeks. J. AIDS 40(4), 422-427 (2005).
25. Lamarca A, Clumeck N, Plattenberg A et al.: Efficacy and safety of a once daily fixed dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral experienced HIV-1 infected patients (CAL30001 study) J. Acquir. Immune Defic. Syndr. 41(5), 598-606 (2006).
26. Gallant JE, Rodriguez AE, Weinberg WG et al.: Early virologic nonresponse to tenofovir, abacavir and lamivudine in HIV-infected antiretroviral-naive subjects. J. Infect. Dis. 192(1), 1921-1930 (2005).
27. Landman R, Peytavin G, Descamps D et al.: Low genetic barrier to resistance is a possible cause if early virologic failures in once daily regimen of abacavir, lamivudine and tenofovir: The Tonus study. HIV Clin. Trials 6(6), 291-301 (2005).
28. Paediatric European Network for Treatment of AIDS. Comparison of dual nucleoside analogue reverse transcriptase inhibitor regimes with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomized trial. Lancet 359, 733-740 (2002).
29. Mocroft A, Devereux H, Kinloch-de-Loes S et al.: Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimes in complete clinic populations. AIDS 14, 1545-1552 (2000).
30. Shlay JC, Visnegarwala F, Bartsch G et al.: Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine versus abacavir and lamivudine. J. AIDS 38(2), 147-155 (2005).
31. Moyle G, Baldwin C, Langroudi B, Mandalia S, Gazzard BG: A 48-week randomized open-label comparison of three abacavir-based substitution approaches in the management of dyslipidaemia and peripheral lipoatrophy. J. AIDS 33(1), 22-28 (2003).
32. Martin A, Smith DE, Carr A et al.: Reversibility of lipoatrophy in HIV infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX extension study. AIDS 18(7), 1029-1036 (2005).
33. GlaxoSmithKline Kivexa™ (abacavir & lamivudine) Product Monograph (2004).
34. Hetherington S, McGuirk S, Powell G et al.: Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23, 1603-1614 (2001).
35. Steckler J, Maenza J, Stevens C et al.: Abacavir hypersensitivity reaction in primary HIV infection. AIDS 20(9), 1269-1274 (2006).
36. Nolan D, Gauderi S, Mallal S: Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J. HIV Ther. 8(2), 6-41 (2003).
37. Mallal S, Nolan D, Witt C et al.: Association between presence of HLA-B5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
38. Reeves I, Churchill D, Fisher M: Clinical Utility of HLA-B*5701 testing in a UK clinic cohort. HIV Med. 7(Suppl. 1), 5 (2006) (Abstract no 019).
39. Bowonwatanuwong C, Warren L, Mosteller M et al.: Association of HLA-B*5701 and hypersensitivity to abacavir in a sample of Thai patients. Antivir. Ther. 3, 61 (2005).
40. Hetherington S, Hughes AR, Mosteller M et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359(9312), 1121-1122 (2002).
41. Phillips EJ, Sullivan JR, Knowles SR, Shear NH: Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 16(16), 2223-2225 (2002).
42. Phillips EJ, Wong GA, Kaul R et al.: Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 119(9), 979-981 (2005).
43. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reaction in the Western Australian HIV cohort study. CID 43(1), 99-102 (2006).